Dr. Klopp on IMRT for Gynecologic Cancers

Article

In Partnership With:

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center discusses intensity-modulated radiation therapy (IMRT) for patients with gynecologic cancers.

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center discusses intensity-modulated radiation therapy (IMRT) for patients with gynecologic cancers.

Among patients who had standard radiation, almost 10% of them had trouble controlling bowel movements, whereas this occurred in only 2% of the patients who had IMRT. According to Klopp, it was surprising how severe the patient experience was.

The community is learning more about patient-reported outcomes that it is more sensitive to many forms of toxicity than physician-reported toxicity, explains Klopp.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine